No | Diagnosis | Grade1
| AC | LN | ER3
| PgR3
| HER-2 | Bcl-2 | E-CD |
---|
1 | IDC | G3 | IDH | N1
| 0 | 0 | 0 | 80% | >90% |
2 | IDC | G2 | none | N1
| 40% | 0 | 0 | 80% | >90% |
3 | IDC | G2 | none | N0
| 10% | 2% | 0 | 70% | >90% |
4 | IDC | G3 | none | N0
| 90% | 50% | 2+ 2
| 100% | >90% |
5 | IDC | G2 | DCIS | N0
| 90% | 1% | 0 | 95% | >90% |
6 | ILC | G2 | LCIS | N0
| 0 | 0 | 0 | 30% | 0 |
7 | ILC | G1 | none | N0
| 80% | 80% | 0 | 100% | 0 |
8 | ILC | G1 | none | N1
| 50% | 0 | 0 | 80% | 0 |
9 | ILC | G2 | LCIS | N1
| 0 | 0 | 0 | <5% | 0 |
10 | ILC | G1 | none | N0
| 50% | 70% | 0 | 80% | 0 |
-
1Tumors were graded using the Nottingham combined histologic grading system.
-
2No gene amplification was detected by fluorescent in situ hybridization.
-
3A complete H-score was calculated by summing the products of the percentage cells stained at a given staining intensity (0–100) and the staining intensity (0–3).
- AC, accompanying changes; DCIS, ductal carcinoma in situ; E-CD, E-cadherin; ER, estrogen receptor; IDC, invasive ductal carcinoma, IDH, intraductal hyperplasia; ILC, invasive lobular carcinoma; LCIS, lobular carcinoma in situ; LN, lymph node; PgR, progesterone receptor.